A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

doi:10.1038/s41467-018-06036-0

GSTDTAP > 资源环境科学

DOI	10.1038/s41467-018-06036-0
	A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
	Wu, Xiujuan; Tang, Peng; Li, Shifei; Wang, Shushu; Liang, Yueyang; Zhong, Ling; Ren, Lin; Zhang, Ting; Zhang, Yi
	2018-02-26
发表期刊	NATURE COMMUNICATIONS
ISSN	2041-1723
出版年	2018
卷号	9
文章类型	Article
语种	英语
国家	Peoples R China
英文摘要	Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.
领域	资源环境
收录类别	SCI-E
WOS记录号	WOS:000426049100005
WOS关键词	PATHOLOGICAL COMPLETE RESPONSE ; ARTERIAL CHEMOEMBOLIZATION ; ANTITUMOR-ACTIVITY ; CHEMOTHERAPY ; DOCETAXEL ; CARBOPLATIN ; EPIRUBICIN ; PACLITAXEL ; CISPLATIN ; DOXORUBICIN
WOS类目	Multidisciplinary Sciences
WOS研究方向	Science & Technology - Other Topics
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/203985
专题	资源环境科学
作者单位	Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China
推荐引用方式 GB/T 7714	Wu, Xiujuan,Tang, Peng,Li, Shifei,et al. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer[J]. NATURE COMMUNICATIONS,2018,9.
APA	Wu, Xiujuan.,Tang, Peng.,Li, Shifei.,Wang, Shushu.,Liang, Yueyang.,...&Zhang, Yi.(2018).A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.NATURE COMMUNICATIONS,9.
MLA	Wu, Xiujuan,et al."A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer".NATURE COMMUNICATIONS 9(2018).